Published in Sci Rep on July 28, 2016
Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med (2014) 16.45
Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ (1978) 9.23
A case of Ebola virus infection. Br Med J (1977) 7.40
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature (2014) 6.94
Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med (2015) 5.92
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 3.47
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med (2012) 2.98
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A (2012) 2.83
Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72
Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol (1995) 2.56
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med (2013) 2.10
Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs (2009) 2.03
Severe adverse drug reaction following Crotalidae Polyvalent Immune Fab (Ovine) administration for copperhead snakebite. Ann Pharmacother (2014) 1.98
Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. J Infect Dis (1999) 1.92
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
The pathology of experimental Ebola virus infection in monkeys. J Pathol (1978) 1.66
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis (2008) 1.30
Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep (2014) 1.24
Post-exposure therapy of filovirus infections. Trends Microbiol (2014) 1.17
Experimental therapy of filovirus infections. Antiviral Res (2002) 1.16
Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef (2011) 1.09
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Comment: severe anaphylactic reaction following crotalidae polyvalent immune fab (ovine) administration for copperhead snakebite. Ann Pharmacother (2015) 1.08
US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ (2014) 1.07
Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran. Genome Announc (2014) 1.07
Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res (2009) 1.06
First Ebola treatment is approved by WHO. BMJ (2014) 1.03
Recurrence and reinfection-a new paradigm for the management of Ebola virus disease. Int J Infect Dis (2015) 1.03
Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother (2010) 1.02
Ebola virus transmission in guinea pigs. J Virol (2014) 1.01
Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome Biol (2014) 1.01
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. J Virol (2015) 1.00
High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis (2011) 0.99
Public health aspects of snakebite care in West Africa: perspectives from Nigeria. J Venom Anim Toxins Incl Trop Dis (2013) 0.96
Rethinking the discharge policy for Ebola convalescents in an accelerating epidemic. Am J Trop Med Hyg (2014) 0.96
Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J Virol (2013) 0.94
Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Rep (2015) 0.94
Potential vaccines and post-exposure treatments for filovirus infections. Viruses (2012) 0.94
Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun (2011) 0.89
Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. Euro Surveill (2015) 0.88
Antibody therapy for Ebola: is the tide turning around? Hum Vaccin Immunother (2014) 0.84
Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antiviral Res (2012) 0.82
Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency. J Virol (2015) 0.81
Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis (2015) 0.81
Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis (2015) 0.80
Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana. J Chromatogr A (2015) 0.79
Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013-2015. Virus Res (2015) 0.76
Protecting Healthcare Personnel from Acquiring Ebola Virus Disease. Infect Control Hosp Epidemiol (2015) 0.76
Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Crit Rev Biotechnol (2015) 0.76